Patents Represented by Attorney Daryl D. Muenchau
-
Patent number: 8249995Abstract: This method uses a jobs-based social networking website and the monetary incentive of a “job reward” to get friends, relatives and other visitors to the website to offer a personal introduction to a company insider in exchange for the exclusive contractual right to receive a contingent referral fee if the introduced person starts a job with the named company within the time period set forth in the contract. Ideally, hundreds if not thousands of people will review a person's profile on the social networking website. If the job candidate is qualified, many offers of introduction will be made. The jobseeker can accept many offers but only one offer of introduction per company or non-profit entity in a given time period. Since the job candidate will only start one job within that relatively short period of time, only one referral fee will need to be paid.Type: GrantFiled: April 21, 2009Date of Patent: August 21, 2012Inventor: Robert Anthony Sheperd
-
Patent number: 8217025Abstract: The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol, 4?-fluoro-17?-ethynylandrost-5-ene-3?,7?,17?-triol and 4?-fluoro-17?-ethynylandrost-5-ene-3?,17?-triol-7-one.Type: GrantFiled: November 19, 2007Date of Patent: July 10, 2012Assignee: Harbor Therapeutics, Inc.Inventors: Jaime Flores-Riveros, James M. Frincke, Christopher Reading, Dwight Stickney, Clarence N. Ahlem
-
Patent number: 8022234Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.Type: GrantFiled: September 30, 2009Date of Patent: September 20, 2011Assignee: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Patent number: 7910571Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: October 13, 2006Date of Patent: March 22, 2011Assignee: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Patent number: 7863261Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: January 4, 2011Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Patent number: 7842680Abstract: The instant invention provides potent antiandrogen compounds, such as 3?-acetoxyandrost-1,5-diene-17-ethylene ketal and 3?-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally, inventive compounds may be used to treat antiandrogen induced withdrawal syndrome.Type: GrantFiled: March 17, 2009Date of Patent: November 30, 2010Assignee: Harbor BioSciences, Inc.Inventors: Henry A. Lardy, Padma Marwah, Ashok Marwah
-
Patent number: 7776845Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: August 17, 2010Assignee: Harbor Biosciences, Inc.Inventor: James M. Frincke
-
Patent number: 7723532Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.Type: GrantFiled: October 23, 2006Date of Patent: May 25, 2010Assignee: Harbor BioSciences, Inc.Inventors: James M. Frincke, Christopher L. Reading, Clarence N. Ahlem
-
Patent number: 7696189Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: April 13, 2010Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventor: James M. Frincke
-
Patent number: 7691835Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: April 6, 2010Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventor: James M. Frincke
-
Patent number: 7547687Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: GrantFiled: February 12, 2007Date of Patent: June 16, 2009Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventors: Christopher L. Reading, Clarence N. Ahlem, Dominick L. Auci, Charles Dowding, James M. Frincke, Mei Li, Theodore M. Page, Dwight R. Stickney, Richard J. Trauger, Steven K. White
-
Patent number: 7241753Abstract: The present invention relates to the field of cancer, and in particular hormone dependent cancers including, but not limited to prostate, breast, endometrial, ovarian, thyroid, bone, and testis. The present invention also relates to the use of steroid analogues, and in particular analogues of ?5-androstene-3-?, 17?-diol, and its epimer ?5-androstene-3-?, 17?-diol for the treatment and prevention of cancer.Type: GrantFiled: February 26, 2001Date of Patent: July 10, 2007Inventor: Roger M. Loria
-
Patent number: 6794374Abstract: Arthritis can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such a &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.Type: GrantFiled: November 27, 2000Date of Patent: September 21, 2004Assignee: Humanetics CorporationInventor: Charles E. Weeks
-
Patent number: 6667299Abstract: The invention provides compositions comprising, 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.Type: GrantFiled: March 23, 2000Date of Patent: December 23, 2003Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventors: Clarence Nathaniel Ahlem, Luis Daniel dos Anjos de Carvalho, William Heggie
-
Patent number: 5922695Abstract: Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.Type: GrantFiled: July 25, 1997Date of Patent: July 13, 1999Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Kenneth C. Cundy, Joseph P. Dougherty, Choung U. Kim, Reza Oliyai, Valentino J. Stella
-
Patent number: 5886179Abstract: Nucleotide phosphonate esters characterized by the presence of an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise an ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.Type: GrantFiled: December 29, 1995Date of Patent: March 23, 1999Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Norbert W. Bischofberger, Robert J. Jones, William A. Lee, Ernest J. Prisbe
-
Patent number: 5830653Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Assignee: Gilead Sciences, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Patent number: 5817781Abstract: The invention relates to novel modified oligonucleotides, the construction thereof, and their use in oligonucleotide-based therapies. More specifically, the invention is to novel oligonucleotides having modified internucleoside linkages which are resistant to nucleases, having enhanced ability to penetrate cells, and which are capable of binding target oligonucleotide sequences in vitro and in vivo. The modified oligonucleotides of the invention are particularly useful in oligonucleotide-based therapies utilizing the modified oligonucleotides to interrupt protein synthesis or transcription or to otherwise inactivate messenger RNA or double stranded DNA.Type: GrantFiled: June 1, 1992Date of Patent: October 6, 1998Assignee: Gilead Sciences, Inc.Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Jeff Pudlo, Robert J. Jones
-
Patent number: 5798340Abstract: Nucleotide analogs characterized by the presence of an amidate lirked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolysed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for the synthesis and use are described.Type: GrantFiled: May 6, 1996Date of Patent: August 25, 1998Assignee: Gilead Sciences, Inc.Inventors: Norbert W. Bischofberger, Robert J. Jones, Murty N. Arimilli, Michael S. Louie, Ernest J. Prisbe, William A. Lee
-
Patent number: 5792608Abstract: Oligomers are disclosed which have modified internucleotide linkages and can form triplex and duplex structures by binding to complementary nucleic acid sequences. The oligomers of the invention may be incorporated into carriers and may be constructed to have any desired sequence. Compositions of the invention can be used for diagnostic purposes in order to detect viruses or disease conditions.Type: GrantFiled: April 6, 1995Date of Patent: August 11, 1998Assignee: Gilead Sciences, Inc.Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Robert J. Jones, Jeff Pudlo, John Munger